These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

622 related items for PubMed ID: 27462149

  • 21. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension.
    Fujita H, Fukumoto Y, Saji K, Sugimura K, Demachi J, Nawata J, Shimokawa H.
    Heart Vessels; 2010 Mar; 25(2):144-9. PubMed ID: 20339976
    [Abstract] [Full Text] [Related]

  • 22. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.
    Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, Seeger W.
    Am J Respir Crit Care Med; 1999 Aug; 160(2):600-7. PubMed ID: 10430735
    [Abstract] [Full Text] [Related]

  • 23. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension.
    Haraldsson s A, Kieler-Jensen N, Ricksten SE.
    Anesth Analg; 2001 Dec; 93(6):1439-45, table of contents. PubMed ID: 11726420
    [Abstract] [Full Text] [Related]

  • 24. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
    Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbrück B, Grimminger F, Seeger W.
    Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
    [Abstract] [Full Text] [Related]

  • 25. Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease.
    Faria-Urbina M, Oliveira RKF, Agarwal M, Waxman AB.
    Lung; 2018 Apr; 196(2):139-146. PubMed ID: 29275453
    [Abstract] [Full Text] [Related]

  • 26. Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction.
    van Duin RWB, Houweling B, Uitterdijk A, Duncker DJ, Merkus D.
    Am J Physiol Heart Circ Physiol; 2018 Feb 01; 314(2):H170-H179. PubMed ID: 28986358
    [Abstract] [Full Text] [Related]

  • 27. Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation.
    Calcaianu G, Canuet M, Schuller A, Enache I, Chaouat A, Kessler R.
    Respiration; 2016 Feb 01; 91(1):9-17. PubMed ID: 26492415
    [Abstract] [Full Text] [Related]

  • 28. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension.
    Ghofrani HA, Friese G, Discher T, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F, Lohmeyer J.
    Eur Respir J; 2004 Feb 01; 23(2):321-6. PubMed ID: 14979511
    [Abstract] [Full Text] [Related]

  • 29. Phase 1 Study of MK-5475, an Inhaled Soluble Guanylate Cyclase Stimulator, in Participants with Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.
    Bajwa EK, Cislak D, Kumar A, Li D, Messina EJ, Reynders T, Denef JF, Corcea V, Buch KP, Lai E, Stoch SA.
    Int J Chron Obstruct Pulmon Dis; 2024 Feb 01; 19():1105-1121. PubMed ID: 38803412
    [Abstract] [Full Text] [Related]

  • 30. Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds.
    Hagan G, Pepke-Zaba J.
    Expert Rev Respir Med; 2011 Apr 01; 5(2):163-71. PubMed ID: 21510727
    [Abstract] [Full Text] [Related]

  • 31. Potential Role of CT Metrics in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension.
    Ando K, Kuraishi H, Nagaoka T, Tsutsumi T, Hoshika Y, Kimura T, Ienaga H, Morio Y, Takahashi K.
    Lung; 2015 Dec 01; 193(6):911-8. PubMed ID: 26453478
    [Abstract] [Full Text] [Related]

  • 32. Contribution of pulmonary surfactant with inhaled nitric oxide for treatment of pulmonary hypertension.
    Kusuda S, Kim TJ, Koriyama T, Matsunami S, Nakanishi H.
    Pediatr Int; 2006 Oct 01; 48(5):459-63. PubMed ID: 16970783
    [Abstract] [Full Text] [Related]

  • 33. A Comparative Investigation of the Pulmonary Vasodilating Effects of Inhaled NO Gas Therapy and Inhalation of a New Drug Formulation Containing a NO Donor Metabolite (SIN-1A).
    Oláh A, Barta BA, Ruppert M, Sayour AA, Nagy D, Bálint T, Nagy GV, Puskás I, Szente L, Szőcs L, Sohajda T, Zima E, Merkely B, Radovits T.
    Int J Mol Sci; 2024 Jul 22; 25(14):. PubMed ID: 39063223
    [Abstract] [Full Text] [Related]

  • 34. Sustained pulmonary vasodilation after inhaled nitric oxide for hypoxic pulmonary hypertension in swine.
    Emil S, Kanno S, Berkeland J, Kosi M, Atkinson J.
    J Pediatr Surg; 1996 Mar 22; 31(3):389-93. PubMed ID: 8708909
    [Abstract] [Full Text] [Related]

  • 35. [Inhaled nitric oxide for the treatment of ARDS].
    Lohbrunner H, Deja M, Busch T, Spies CD, Rossaint R, Kaisers U.
    Anaesthesist; 2004 Aug 22; 53(8):771-82; quiz 783-4. PubMed ID: 15257405
    [Abstract] [Full Text] [Related]

  • 36. Hemodynamic effects of inhaled nitric oxide using pulse delivery and continuous delivery systems in pulmonary hypertension.
    Kitamukai O, Sakuma M, Takahashi T, Nawata J, Ikeda J, Shirato K.
    Intern Med; 2002 Jun 22; 41(6):429-34. PubMed ID: 12135173
    [Abstract] [Full Text] [Related]

  • 37. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside.
    Kieler-Jensen N, Lundin S, Ricksten SE.
    J Heart Lung Transplant; 1995 Jun 22; 14(3):436-43. PubMed ID: 7654728
    [Abstract] [Full Text] [Related]

  • 38. Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension.
    Curran RD, Mavroudis C, Backer CL, Sautel M, Zales VR, Wessel DL.
    Ann Thorac Surg; 1995 Dec 22; 60(6):1765-71. PubMed ID: 8787478
    [Abstract] [Full Text] [Related]

  • 39. The acute effect of inhaled nitric oxide on the exercise capacity of patients with advanced interstitial lung disease: a randomized controlled trial.
    Freidkin L, Kramer MR, Rosengarten D, Izhakian S, Taieb S, Pertzov B.
    BMC Pulm Med; 2024 May 10; 24(1):226. PubMed ID: 38724947
    [Abstract] [Full Text] [Related]

  • 40. Inhaled nitric oxide does not improve cardiac or pulmonary function in patients with an exacerbation of chronic obstructive pulmonary disease.
    Baigorri F, Joseph D, Artigas A, Blanch L.
    Crit Care Med; 1999 Oct 10; 27(10):2153-8. PubMed ID: 10548198
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.